Sterne, Kessler, Goldstein & Fox Elects Five New DirectorsIPWatchdog.com… International Trade Commission investigations under §337, evaluating patent portfolios, drafting patent applications, and prosecuting interferences. He also manages the pre… Continue reading
Sterne, Kessler, Goldstein & Fox Elects Five New DirectorsIPWatchdog.com… International Trade Commission investigations under §337, evaluating patent portfolios, drafting patent applications, and prosecuting interferences. He also manages the pre… Continue reading
Eureka Therapeutics Closes $60 Million in Series D Financing to Advance Proprietary ARTEMIS™ T Cell Receptor …Business Wire (press release)This financing represents an important validation of our strategy, and provides us the resources to advance our… Continue reading
Medical XpressNot just a stem cell marker – Medical XpressMedical XpressThe protein CD34 is predominantly regarded as a marker of blood-forming stem cells but it helps with migration to the bone marrow too.and more »… Continue reading
Endpoints News |
Celgene is buying cancer drugmaker Juno Therapeutics for $9 billion
Markets Insider One challenge these therapies still face is how toxic they can be. CAR–T’s side effects can be deadly. In May 2017, Kite disclosed that one person had died in a clinical trial for its late-stage CAR–T therapy from cerebral edema, a condition in which … Celgene to buy Juno for $9 billion to boost CAR–T expertiseReuters UPDATED: Celgene bags CAR–T player Juno in $9B buyout as biotech M&A suddenly explodesEndpoints News Shares of biotech Juno, already up 50% on deal hopes, skyrocket on actual Celgene $9 billion offerCNBC Business Wire (press release) –Financial Times all 128 news articles » |
Endpoints News |
UPDATED: Celgene bags CAR–T player Juno in $9B buyout as biotech M&A suddenly explodes
Endpoints News Leerink in particular was looking for Celgene to fork over $93 a share, which is what Celgene pegged the price at when it bought a minority share in the biotech. CAR-T has been one of the big success stories for biotech, offering a new approach to … Muscle CAR? Celgene’s $9B offer for Juno starts pundits weighing tractionBioWorld Online Celgene to buy Juno for $9 billion to boost cancer pipelineReuters Shares of biotech Juno, already up 50% on deal hopes, skyrocket on actual Celgene $9 billion offerCNBC Madison.com –Zacks Investment Research –Zacks Investment Research all 241 news articles » |